Does abiraterone cause renal impairment?

Does Abiraterone Cause Kidney Impairment?

Abiraterone itself does not directly cause kidney impairment based on FDA pharmacokinetic data, but rare cases of acute kidney injury have been reported, typically in the context of drug interactions (particularly with statins) or rhabdomyolysis. The FDA label explicitly states that systemic exposure to abiraterone did not increase in patients with end-stage renal disease on dialysis compared to those with normal renal function 1.

Key Evidence from FDA Drug Label

The FDA-approved labeling provides critical pharmacokinetic data:

• No dose adjustment needed for renal impairment: Pharmacokinetic studies in patients with end-stage renal disease on hemodialysis (N=8) showed that systemic exposure to abiraterone after a single 1,000 mg dose did not increase compared to subjects with normal renal function 1
• This indicates abiraterone is not primarily renally cleared and does not accumulate in renal impairment

Rare Case Reports of Acute Kidney Injury

While the drug label shows no direct renal toxicity, several case reports document acute kidney injury (AKI) associated with abiraterone:

Rhabdomyolysis-Mediated AKI

• Most concerning mechanism: Multiple case reports describe rhabdomyolysis-induced AKI when abiraterone is combined with statins (particularly rosuvastatin) 2, 3, 4
• The proposed mechanism involves abiraterone's inhibition of the hepatic transporter OATP1B1, which increases plasma concentrations of statins, leading to muscle toxicity 2
• One case showed severe rhabdomyolysis (CK 44,476 IU/L) with AKI that resolved after discontinuing both abiraterone and rosuvastatin 4
• Importantly, re-initiation of abiraterone alone (without statin) did not cause recurrence of muscle toxicity 2

Direct Drug-Induced AKI

• One case report described biopsy-proven acute tubular damage in a patient on abiraterone and relugolix, though causality remains uncertain 5
• Another case showed abiraterone-associated rhabdomyolysis without concurrent statin use, though the patient had additional risk factors 3

Clinical Context: Mineralocorticoid Effects vs. Direct Nephrotoxicity

Important distinction: Abiraterone causes mineralocorticoid excess (hypertension, hypokalemia, peripheral edema) due to CYP17 inhibition, which is why concurrent steroid therapy is mandatory 6, 7. However, these are not direct renal toxicity but rather predictable pharmacologic effects that require monitoring.

The NCCN guidelines recommend:

• Monthly monitoring of liver function, potassium, phosphate levels, and blood pressure 6, 7
• Concurrent prednisone 5 mg twice daily or methylprednisolone 4 mg twice daily to prevent mineralocorticoid excess 6, 7

Positive Evidence: Improved Renal Function in Some Cases

Interestingly, two case reports showed improvement in renal function when patients with chronic kidney disease and metastatic castration-resistant prostate cancer were treated with abiraterone after chemotherapy had worsened their renal function 8. This suggests abiraterone may be safer than certain chemotherapy regimens in patients with pre-existing renal disease.

Safety Meta-Analysis

A large individual patient data meta-analysis of 14 randomized trials (4,296 patients) found that serious adverse events (grade 3-4) were actually lower with abiraterone (64.1%) compared to standard of care (71.8%) 9. Renal-specific adverse events were not highlighted as a major concern in this comprehensive safety analysis.

Clinical Recommendations

Monitor for these specific scenarios:

1. Avoid or closely monitor statin combinations: The association between rosuvastatin and abiraterone should be avoided due to OATP1B1 inhibition increasing statin toxicity risk 2

2. Watch for rhabdomyolysis risk factors: In patients with additional risk factors (advanced age, renal impairment, high-dose statins), employ strict monitoring of creatine kinase and renal function 3

3. No dose adjustment needed: Based on FDA pharmacokinetic data, no dose adjustment is required for renal impairment, including end-stage renal disease 1

4. Standard monitoring: Follow NCCN guidelines for monthly monitoring of electrolytes, blood pressure, and liver function—not specifically for direct nephrotoxicity, but for mineralocorticoid effects 6, 7

Common Pitfall to Avoid

Do not confuse the mineralocorticoid effects (hypertension, hypokalemia) with direct nephrotoxicity. These are expected pharmacologic consequences of CYP17 inhibition that are managed with concurrent steroid therapy, not evidence of kidney damage.